Literature DB >> 20120022

Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding.

Sandra Lightle1, Serdar Aykent, Nathan Lacher, Vesselin Mitaksov, Kristine Wells, James Zobel, Theodore Oliphant.   

Abstract

Human IgG2 antibodies may exist in at least three distinct structural isomers due to disulfide shuffling within the upper hinge region. Antibody interactions with Fc gamma receptors and the complement component C1q contribute to immune effector functions. These interactions could be impacted by the accessibility and structure of the hinge region. To examine the role structural isomers may have on effector functions, a series of cysteine to serine mutations were made on a human IgG2 backbone. We observed structural homogeneity with these mutants and mapped the locations of their disulfide bonds. Importantly, there was no observed difference in binding to any of the Fc gamma receptors or C1q between the mutants and the wild-type IgG2. However, differences were seen in the apparent binding affinity of these antibodies that were dependent on the selection of the secondary detection antibody used.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20120022      PMCID: PMC2867015          DOI: 10.1002/pro.352

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  29 in total

1.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

2.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

3.  Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.

Authors:  Kathryn L Armour; Jan G J van de Winkel; Lorna M Williamson; Mike R Clark
Journal:  Mol Immunol       Date:  2003-12       Impact factor: 4.407

4.  The binding site for C1q on IgG.

Authors:  A R Duncan; G Winter
Journal:  Nature       Date:  1988-04-21       Impact factor: 49.962

5.  Variations in the S-S bridges of immunoglobins G: interchain disulfide bridges of gamma G3 myeloma proteins.

Authors:  B Frangione; C Milstein
Journal:  J Mol Biol       Date:  1968-05-14       Impact factor: 5.469

6.  Localization of the binding site for the human high-affinity Fc receptor on IgG.

Authors:  A R Duncan; J M Woof; L J Partridge; D R Burton; G Winter
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

7.  Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.

Authors:  E E Idusogie; L G Presta; H Gazzano-Santoro; K Totpal; P Y Wong; M Ultsch; Y G Meng; M G Mulkerrin
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

8.  Disulphide bridges of the heavy chain of human immunoglobulin G2.

Authors:  C Milstein; B Frangione
Journal:  Biochem J       Date:  1971-01       Impact factor: 3.857

9.  Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis.

Authors:  Martin J Allen; Amy Guo; Theresa Martinez; Mei Han; Gregory C Flynn; Jette Wypych; Yaoqing Diana Liu; Wenyan D Shen; Thomas M Dillon; Christopher Vezina; Alain Balland
Journal:  Biochemistry       Date:  2009-05-05       Impact factor: 3.162

10.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

Authors:  M Brüggemann; G T Williams; C I Bindon; M R Clark; M R Walker; R Jefferis; H Waldmann; M S Neuberger
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  12 in total

1.  Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1.

Authors:  Ashish K Solanki; Yogendra S Rathore; Maulik D Badmalia; Reema R Dhoke; Samir K Nath; Deepak Nihalani
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

2.  Disulfide scrambling in IgG2 monoclonal antibodies: insights from molecular dynamics simulations.

Authors:  Xiaoling Wang; Sandeep Kumar; Satish K Singh
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

Review 3.  Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins.

Authors:  Jude C Lakbub; Joshua T Shipman; Heather Desaire
Journal:  Anal Bioanal Chem       Date:  2017-12-18       Impact factor: 4.142

4.  The solution structure of the human IgG2 subclass is distinct from those for human IgG1 and IgG4 providing an explanation for their discrete functions.

Authors:  Gar Kay Hui; Antoni D Gardener; Halima Begum; Charles Eldrid; Konstantinos Thalassinos; Jayesh Gor; Stephen J Perkins
Journal:  J Biol Chem       Date:  2019-05-14       Impact factor: 5.157

Review 5.  Vascular Considerations for Amyloid Immunotherapy.

Authors:  Kate E Foley; Donna M Wilcock
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-21       Impact factor: 6.030

6.  Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks.

Authors:  Lisa M Jones; Hao Zhang; Weidong Cui; Sandeep Kumar; Justin B Sperry; James A Carroll; Michael L Gross
Journal:  J Am Soc Mass Spectrom       Date:  2013-03-13       Impact factor: 3.109

Review 7.  IgG subclasses and allotypes: from structure to effector functions.

Authors:  Gestur Vidarsson; Gillian Dekkers; Theo Rispens
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

8.  Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

Authors:  Ann L White; H T Claude Chan; Ruth R French; Jane Willoughby; C Ian Mockridge; Ali Roghanian; Christine A Penfold; Steven G Booth; Ali Dodhy; Marta E Polak; Elizabeth A Potter; Michael R Ardern-Jones; J Sjef Verbeek; Peter W M Johnson; Aymen Al-Shamkhani; Mark S Cragg; Stephen A Beers; Martin J Glennie
Journal:  Cancer Cell       Date:  2014-12-11       Impact factor: 31.743

9.  Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.

Authors:  Jennifer D Könitzer; Annette Sieron; Angelika Wacker; Barbara Enenkel
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

10.  Three-dimensional structure of the human myeloma IgG2.

Authors:  Sergey Ryazantsev; Vladimir Tischenko; Christopher Nguyen; Vyacheslav Abramov; Vladimir Zav'yalov
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.